EQUITY.GURU podcast

Welcome once again to Equity Guru’s Short and Sweet where we distill our in-depth interviews into solid nuggets of gold, enabling you to drink down the cream of each conversation in one delectable 5-minute gulp. In this week’s three-part episode, we are drawing from The Jody Vance Experience where Jody speaks with Brigadier Gold (BRG.V) president, CEO and director, Ranjeet Sundher, PredictMedix (PMED.C) CEO, Dr. Rahul Kushwah and EarthRenew (ERTH.C) CEO and director, Keith Driver. Listen in!   Full disclosure: Brigadier Gold, PredictMedix and EarthRenew are Equity.Guru marketing clients.

Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval. Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors. Here are the highlights!

Welcome to the second installment! Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval. Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors. Listen in!

Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval. Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors. Tune in!

Time for part 2! Sixth Wave Innovations (SIXW.C), a world leader in molecular detection and extraction, is working to disrupt the market for Covid rapid testing as well as mineral extraction for gold mining and last but not least, cannabis extraction. Equity Guru's own Chris Parry spoke with company president, CEO and founder, Jonathan Gluckman, PhD., to get an inside look at the company and what potential it holds for investors. Tune in!

Sixth Wave Innovations (SIXW.C), a world leader in molecular detection and extraction, is working to disrupt the market for Covid rapid testing as well as mineral extraction for gold mining and last but not least, cannabis extraction. Equity Guru's own Chris Parry spoke with company president, CEO and founder, Jonathan Gluckman, PhD., to get an inside look at the company and what potential it holds for investors. Tune in!

This is the final segment where Pure Extracts Technologies (PULL.C) CEO, Ben Nikolaevsky, speaks with Equity Guru's own, Chris Parry, to outline the companies cross market potential in plant-based extraction. Tune in!

It's not all about legal cannabis anymore, Pure Extracts Technologies (PULL.C) CEO, Ben Nikolaevsky, speaks with Equity Guru's own, Chris Parry, to outline the companies cross market potential in plant-based extraction. Tune in!

KWESST is a Canadian military tech company that is “making dumb weapons smart” by developing proprietary technology for the military and homeland security markets. The total Global Defense Budget is estimated at USD $1.8 Trillion in 2020 and the market is expected to grow to USD $2.3 Trillion by 2028. “Thirteen conflicts are identified as top priorities for the United States,” states The Council on Foreign relations. KWESST has a diversified product line, based on a single core technology, called Micro Integrated Sensor Systems Technology (MISST), which involves miniaturized sensors, optics, ballistics and software which claims to significantly jack-up mission capability. In this pt. 2 podcast, Equity Guru’s Guy Bennett talks to David Luxton, Executive Chairman of KWESST about laser warfare, shot counters, the management team, global markets, 2020 objectives, share structure and KWESST’s “Blue Sky Story”. Full Disclosure:  KWESST is an Equity Guru marketing client.

Small caps in Canada, especially in tech, are full of faux-companies. You know,the kind where the problem being solved isn’t really a problem, and the“technology” being advertised is actually five years old. PredictMedix (PMED.C) isn’t one of them. The last time I wrote about PredictMedix, I made an argument about: The resilience of pharmaceuticals as a sector, and The scalability of the tech, and hence the business Since then, the stock has been pumped. Listen in as Arth talks with Kapil Raval!

KWESST is a Canadian military tech company that is “making dumb weapons smart”. KWESST develops and markets proprietary technology to sell into the military and homeland security market. Conceptually and financially, KWESST has a tight, elegant structure. Publicly listed military tech companies typically use a shot gun approach to product development: Body armour? We got it. Armed robotics? We got it. Amphibious rifles? Just one – or a whole case? KWESST has a diversified product line, based on a single core technology, called Micro Integrated Sensor Systems Technology (MISST), which involves miniaturized sensors, optics, ballistics and software which claims to significantly jack-up mission capability. In this podcast, Equity Guru’s Guy Bennett talks to David Luxton, Executive Chairman of KWESST. Note: This company is completing a $2 million go-public financing. We believe KWESST is committed to building a wide shareholder base, which means KWESST may be receptive to retail investors with modest net worth. Small cap investing vets will know, this isn't always the case. If you are interested, contact Jose Estevez, VP, Institutional Sales at PI financial at jestevez@pifinancial.com.  Tell him you listened to this podcast and Equity Guru sent you. Full Disclosure: KWESST is an Equity Guru marketing client.

On April 14, 2020 Last Mile Holdings (MILE.V) announced a new delivery service for restaurants, grocery stores, and other local businesses. It’s a smart adaptive mechanism to offer local business an alternative to being gouged by food delivery companies. Gotcha’s sit-down scooters and/or e-bikes will be available to these hard-hit vendors for $15 per day to deliver goods to customers – allowing local businesses to cut out 3rd-party delivery services, which typically charge 20 to 30 percent per order. “Last Mile Holdings has been making food deliveries on our sit-down scooter for over a year with food delivery partners reporting over 30% efficiency improvements over deliveries that were made with a car or pedal bike,” stated Max Smith, Last Mile CEO. Last Mile is a brand new company – so new it’s still bathed in amniotic fluid. In this Last Mile Podcast, Guy Bennett talks to Mr. Smith about the timing of MILE’s IPO, worker safety, partnerships with restaurants, food delivery apps and Last Mile’s enticing value proposition to retailers. Full Disclosure:  Last Mile is an Equity Guru marketing client Listen in!

Last Mile Holdings (MILE.V) suffered the misfortune of beginning life as a publicly traded company on March 9, 2020 – a day when the Great Stock Market Crash of 2020 began – the DJIA falling 2,013 points that day to 23,851. On March 5, 2020, Last Mile announced the acquisition of Gotcha Mobility, focusing on university campuses in the U.S. Gotcha has been a micro-mobility leader for 10 years, starting with electric rideshare vehicles and pedal bikes, then expanding into e-bikes, e-scooters, and e-trikes. With a focus on university and small to midsize municipalities, Gotcha has secured permits to deploy approximately 20,000 vehicles, 80% of which are exclusive. With 80 combined locations, MILE is the third largest micro-mobility company by location in North America, after Lime and Bird. “Last Mile’s OJO chain is growing fast, and in a controlled, responsible, and municipally welcomed fashion,” stated Equity Guru’s Chris Parry on March 13, 2020, “It’s a half billion dollar company in the making, in a $9 million market cap package”. In the pt.1 Last Mile Podcast, Equity Guru’s Guy Bennett talked to Last Mile CEO Max Smith about the importance of “exclusive contracts”, the company’s prestigious seed investors – and how innovative technologies create new revenue streams. In this p.2 Last Mile Podcast, Mr. Bennett talks to Mr. Smith about insurance, app functionality, retail partnerships, manufacturing, expansion capital and 2020 milestones. Listen in! Full Disclosure: Last Mile is an Equity Guru marketing client

At 6:30 a.m. Monday, March 9, 2020 Last Mile Holdings (MILE.V) will begin its life as a publicly traded company. What’s “Last Mile” about? Think Zipcar but with scooters and e-bikes. This service is “on trend”. Unlike previous generations, Millennials don’t perceive car ownership as hip.  They prefer access to ownership. Case in point: Millennials account for about 23% of the general population but comprise more than 50% of Zipcar's members. Renting an electric scooter is environmentally friendly and leaves you free from the logistical and financial burden of vehicle ownership. “Purchases of cars by the younger set are dropping precipitously,” confirms Bloomberg News, “Survey after survey shows that the latest generations don’t put car ownership high on their list of things to do.” On March 5, 2020, Last Mile announced the acquisition of Gotcha Mobility, focusing on university campuses in the U.S. MILE now has the broadest product profile in the micro-mobility space, featuring a pedal bike, e-bike, standup scooter, seated scooter and trike," stated Max Smith, CEO of MILE. "Offering multi-modal solutions is key to expanding our network." Gotcha has secured permits to deploy 20,000 vehicles, 80% of which are exclusive. This acquisition positions MILE as the third largest micro-mobility company by location in North America, after Lime and Bird. In this podcast, Equity Guru’s Guy Bennett talks to Last Mile CEO Max Smith about the importance of “exclusive contracts”, the company’s prestigious seed investors - and innovative technologies will create new revenue streams. Listen in! Full Disclosure: Last Mile is an Equity Guru marketing client

  Yield Growth (BOSS.C) has developed a portfolio of cannabis-based “wellness formulas” – under the Urban Juve brand – with a dedicated range of skin and body care formulations.” On January 23, 2010, Yield Growth announced that Urban Juve's hemp infused lip balm was placed in hundreds of thousands of IPSY Glam Bags, garnering 15,000 consumer reviews with an overall consumer rating of 4.5 stars out of 5. Through its subsidiaries, Yield Growth has over 200 proprietary beauty, wellness, edibles and beverage formulas for commercialization. Expansion strategy is also focusing on opportunities in functional mushrooms and psychedelic research. In this, part 2 of a two-part interview, Penny White, CEO of Yield Growth, spoke with Equity.Guru’s Guy Bennett about the target market for Urban Juve, branding, packaging, South America, regulation, topicals, Wright & Well, mushrooms and the potential end game for BOSS. Listen in!